Neurofibroma
MONDO:0016755An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.
Also known as: neurofibroma, neurofibroma (WHO grade I), neurofibroma, benign, NFIB
1516 clinical trials for this condition and its sub-types, 17 tagged with Neurofibroma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neurofibroma
-
Neurofibrosarcoma 33 trials
-
Plexiform neurofibroma 29 trials
-
Atypical neurofibroma 4 trials
-
Pacinian tumor 0 trials
-
Cellular neurofibroma 0 trials
-
Epithelioid neurofibroma 0 trials
-
Mediastinum neurofibroma 0 trials
-
Neurofibroma of gallbladder 0 trials
-
Neurofibroma of spinal cord 0 trials
-
Neurofibroma of the esophagus 0 trials
-
Neurofibroma of the heart 0 trials
-
New drug shows promise for shrinking painful NF1 tumors
Disease control OngoingThis study tests a drug called mirdametinib in 114 adults and children with a genetic condition called NF1 that causes nerve tumors (plexiform neurofibromas) that cannot be removed by surgery and cause serious problems. The drug works by blocking a protein that helps tumors grow.…
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Fat-Dissolving drug may shrink NF1 skin tumors
Symptom relief By invitation onlyThis early-stage trial tests whether monthly injections of Kybella (a drug that dissolves fat) can safely shrink skin tumors in people with Neurofibromatosis Type 1. Up to 15 adults will receive up to 6 monthly treatments, and researchers will compare treated and untreated tumors…
Phase 1 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
10-Year NF1 study aims to unlock secrets of rare genetic disorder
Knowledge-focused OngoingThis natural history study follows 259 children, adolescents, and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers will track tumor growth, monitor quality of life, and perform genetic testing to better understand how the disease changes over time. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Blood test could spot hidden tumors in NF1 patients
Knowledge-focused By invitation onlyThis study aims to find blood-based biomarkers that signal the presence and size of plexiform neurofibromas in people with Neurofibromatosis type 1 (NF1). Researchers will collect blood samples and use whole-body MRI to compare biomarker levels in 200 participants with different …
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
500 NF1 patients join study to track skin tumors over 5 years
Knowledge-focused OngoingThis study follows 500 people with neurofibromatosis type 1 (NF1) to see how their skin tumors (called cutaneous neurofibromas) grow and change over time. Researchers use 3D whole-body photography to track tumor number and size each year. The goal is to better understand these tu…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC